Diabetes patients in the US will have greater flexibility in managing insulin delivery after Insulet announced its Omnipod pump is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous ...

"FreeStyle Libre technology was designed from the start to be affordable and accessible," said Jared Watkin, senior vice president for Abbott's diabetes care business. "We've been focused on ...

Abbott announced yesterday that its recently cleared FreeStyle Libre 2 integrated continuous glucose monitoring (CGM) system is now covered by the Centers for Medicare and Medicaid Services (CMS), and ...

The US Food and Drug Administration (FDA) has tagged Abbott’s recent recall of its faulty FreeStyle Libre 3 sensors as Class I, the most serious designation the agency can hand out for a recall. The ...

Fresh off receiving a long-awaited FDA clearance for its FreeStyle Libre 3 system, Abbott has racked up yet another major win for the continuous glucose monitor. Clinical results presented at the ...

The FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor1, with readings sent directly to a smartphone every minute.2 Designed for access and affordability, the FreeStyle ...

Data from Abbott’s REFLECT study show for the first time that the use of its continuous glucose monitoring technology, Freestyle Libre, can help lessen the severity of cardiovascular complications in ...

They say a rising tide lifts all boats, and that certainly seems to be the case with the new wave of drugs and devices for diabetes management. In a recent analysis (PDF), Abbott examined trends in ...

Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the ...

Abbott Laboratories ABT presented late-breaking clinical data that demonstrate the FreeStyle Libre 3 system is the most accurate 14-day continuous glucose monitor. The results were presented at the ...

Please provide your email address to receive an email when new articles are posted on . A voluntary medical device correction warned users of three Abbott FreeStyle Libre readers about the risk of ...

Abbott Labs’ (NYSE:ABT) stock price could gain over 10% if its FreeStyle Libre system captures a 30% share of the blood glucose monitoring market by 2020, according to our estimates. FreeStyle Libre ...